| Bioactivity | LY256548 (LY25648) is an orally available anti-ischemic and anti-inflammatory compound with central nervous system activity. LY256548 is an inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and COX, and inhibits A23187 (HY-N6687)-stimulated leukotriene B4 production. LY256548 inhibits bone damage and paw swelling in the rat Freund's complete adjuvant-induced arthritis (FCA) model[1][2]. |
| In Vivo | LY256548 (LY25648) 在大鼠、狗和猴子中的口服吸收率分别为 45%、7% 和 12%，全身生物利用度分别为 6%、0.4% 和 3%[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 107889-31-6 |
| Formula | C19H27NO2S |
| Molar Mass | 333.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ruterbories KJ, et al. Pharmacokinetics of a novel butylated hydroxytoluene-thiazolidinone CNS antiischemic agent LY256548 in rats, mice, dogs, and monkeys. Drug Metab Dispos. 1990 Sep-Oct;18(5):674-9. [2]. Panetta JA, et al. The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2. |